This novel MOA drug is just that. To many side effects for the FDA to approve it so soon. FDA is going to want more answers on Hypotension, Syncope & Anemia. Wasn’t really studied with SGLT-2 inhibitors. FDA will say, “Bring us more information”
Poster is exactly right. I launched Zontivity and Vericiguat reminds me of the same thing. If somehow the FDA does approve it Merck will be pushing Reps to get scripts. Very crowded market full of Generics and proven Branded meds. Hang on tight ladies and gentlemen.
This review is worth while for all Merck Reps who will be selling Vericiguat. Pay particular close attention to the last paragraph. https://www.physiciansweekly.com/hfsa-drilling-down-into-victoria-findings/
